SCHEMBL1320459

SCHEMBL1320459

CCC(C)c1nc(Nc2cccc(O)c2)nc(Nc2cccc(O)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.47
VSIR Q9H7M9 1/20 0.46
CYP19A1 P11511 1/20 0.46
KMT2A Q03164 3/20 0.46
CYP3A4 P08684 2/20 0.46
MEN1 O00255 2/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
APP P05067 1/20 0.46
CYP1A2 P05177 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46
SNCA P37840 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23519872 0.90 IDH2 (0.45) SYKVSIRCYP19A1KMT2ACYP3A4
SCHEMBL7564159 0.81 SYK (0.64) SYKVSIRKMT2ACYP3A4MEN1
SCHEMBL22356493 0.79 SYK (0.62) SYKVSIRKMT2ACYP3A4MEN1
SCHEMBL29381670 0.79 SYK (0.51) SYKVSIRCYP19A1KMT2ACYP3A4
SCHEMBL1318576 0.79 SYK (0.51) SYKVSIRCYP19A1KMT2ACYP3A4
SCHEMBL1320703 0.78 SYK (0.48) SYKVSIRCYP19A1KMT2ACYP3A4
SCHEMBL1318687 0.77 SYK (0.63) SYKKMT2ACYP3A4MEN1HDAC6
SCHEMBL1320141 0.77 PIK3CA (0.50) SYKVSIRCYP19A1KMT2ACYP3A4
SCHEMBL12513290 0.76 CYP3A4 (0.74) SYKKMT2ACYP3A4MEN1MAPT
SCHEMBL29819598 0.76 CYP3A4 (0.74) SYKKMT2ACYP3A4MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275641-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2011-11-10 US claimed
US-8003645-B2 type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives BTG INTERNATIONAL LTD. (GB) 2011-08-23 US claimed
EP-1473289-B1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS BTG INT LTD (GB) 2009-08-05 EP claimed
US-20080182846-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LIMITED (GB) 2008-07-31 US claimed
US-20050054732-A1 Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds BTG INTERNATIONAL LTD. (GB) 2005-03-10 US claimed
EP-1473289-A1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS Sankyo Company, Limited (JP) 2004-11-03 EP claimed
US-20110275640-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2011-11-10 US disclosed
US-20110275641-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2011-11-10 US disclosed
US-8003645-B2 type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives BTG INTERNATIONAL LTD. (GB) 2011-08-23 US disclosed
US-20090286794-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2009-11-19 US disclosed
US-20090286809-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2009-11-19 US disclosed
US-7589105-B2 For example, N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine, 2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine BTG INTERNATIONAL LIMITED (GB) 2009-09-15 US disclosed
EP-1473289-B1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS BTG INT LTD (GB) 2009-08-05 EP disclosed
US-20080182846-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LIMITED (GB) 2008-07-31 US disclosed
US-20050054732-A1 Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds BTG INTERNATIONAL LTD. (GB) 2005-03-10 US disclosed
EP-1473289-A1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS Sankyo Company, Limited (JP) 2004-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054732-A1 Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds NAT1, APP, BACE1 SYK 3519/4885VSIR 4627/4885CYP19A1 3985/4885
US-20110275641-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 SYK 2947/4885VSIR 4755/4885CYP19A1 4096/4885
US-20090286794-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 SYK 2947/4885VSIR 4755/4885CYP19A1 4096/4885
US-20090286809-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 SYK 2947/4885VSIR 4755/4885CYP19A1 4096/4885
US-20080182846-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 SYK 2947/4885VSIR 4755/4885CYP19A1 4096/4885
US-20110275640-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 SYK 2947/4885VSIR 4755/4885CYP19A1 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.